Coherus Files On-Body Pegfilgrastim, Says ‘People Talk’ On Potential Rivals
Amgen’s Neulasta Onpro Device Continues To Hold More Than 40% Of Market
Having previously underlined that it would not tell the market the exact moment it filed its proposed biosimilar pegfilgrastim on-body injector device, Coherus BioSciences has now confirmed a filing was completed late last year.
